Ipsen revamps U.S. sales ops for new cancer push; Gilead taps Mylan to sell HIV meds in India; Noven signs up to market hot-flash drug Brisdelle;

>Ipsen is setting up its own U.S. oncology team to market Somatuline, an acromegaly treatment, for potential new cancer indications; the French drugmaker's CEO will personally oversee the effort, with the help of a newly hired chief of endocrinology and oncology, Cynthia Schwalm. Report

> Gilead Sciences ($GILD) signed up U.S.-based Mylan ($MYL) to market its HIV treatments Viread, Truvada, and Stribild in India, where the U.S.-based generics maker has been expanding production and marketing. Report

> Noven, the U.S. unit of Hisamitsu Pharmaceutical, signed on to co-promote Brisdelle, the recently approved remedy for hot flashes from Shionogi. Report

> ViiV Healthcare, the HIV-oriented joint venture between GlaxoSmithKline ($GSK) and Pfizer ($PFE), launched its new drug Tivicay in the U.K.; it lacks public funding there yet, so for now it's available via private prescription. Report

> New guidances expected this year from the FDA and the HHS Office of Inspector General stand to affect both drug marketing and research. Report

> Biogen Idec ($BIIB) will be gearing up to launch its multiple sclerosis drug in Europe now that regulators there have approved the treatment. Report

> U.K. regulators green-lighted Allergan's ($AGN) Botox injection to treat ankle disability in stroke patients. Report

And Finally... Do patients want biopharma to be part of their social media conversations? Report

Suggested Articles

Rather than accept a filing based on phase 1/2 data, the FDA wants Novartis to run a phase 3 for a market-expanding version of gene therapy Zolgensma.

After sifting through the data, one analyst figures the latest Opdivo-Keytruda showdown in kidney cancer might come down to commercial execution.

Call it a fall sports bounce. TV ad spending bumped up in August with the partial return of professional sports, and that included pharma buyers.